NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 119 filers reported holding NURIX THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,398,040 | -2.6% | 814,000 | +61.5% | 0.59% | -33.9% |
| Q3 2022 | $6,569,000 | -47.9% | 504,144 | -49.3% | 0.89% | -54.6% |
| Q2 2022 | $12,600,000 | -11.1% | 994,492 | -1.7% | 1.97% | +7.5% |
| Q1 2022 | $14,173,000 | -34.1% | 1,011,638 | +36.1% | 1.83% | -15.1% |
| Q4 2021 | $21,517,000 | +172.2% | 743,238 | +181.6% | 2.15% | +74.8% |
| Q3 2021 | $7,906,000 | – | 263,900 | – | 1.23% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ponoi II Management, LLC | 561,574 | $16,825,000 | 24.93% |
| Ponoi Management, LLC | 561,573 | $16,825,000 | 14.94% |
| TRV GP III, LLC | 2,422,549 | $72,580,000 | 13.78% |
| Foresite Capital Management IV, LLC | 1,205,798 | $36,126,000 | 5.32% |
| Foresite Capital Management V, LLC | 451,522 | $13,528,000 | 4.20% |
| WestHill Financial Advisors, Inc. | 283,333 | $8,489,000 | 2.62% |
| DAFNA Capital Management LLC | 306,320 | $9,177,000 | 2.44% |
| Bain Capital Life Sciences Investors, LLC | 1,284,314 | $38,478,000 | 2.39% |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA | 571,212 | $17,113,000 | 2.02% |
| Redmile Group, LLC | 3,093,077 | $92,669,000 | 1.62% |